Novavax says its COVID-19 vaccine appears 89% effective, based on early findings from a British study. According to USA Today, the two-dose vaccine was just 60% effective in the South African trial.
Novavax’s alliance with Sanofi came at an opportune time for the beleaguered vaccine developer. Its protein-based Covid-19 vaccine never reached the revenue highs achieved by the messenger RNA ...
NEW YORK -- The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across the ...
WASHINGTON — The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine but with unusual restrictions. Novavax makes the nation’s only traditional protein-based ...
WASHINGTON (AP) — The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine but with unusual restrictions. Novavax makes the nation’s only traditional ...
Jefferies London Healthcare Conference 2025 November 19, 2025 11:30 AM ESTCompany ParticipantsRuxandra Draghia-Akli - Executive VP ...
Novavax (NVAX) officially handed over U.S. marketing rights for its COVID-19 vaccine, Nuvaxovid, to Sanofi. This milestone triggered a $25 million payment to Novavax and highlights progress in their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback